Weixinkang announced on April 16 that Inner Mongolia Baiyi Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Drug Clinical Trial Approval Notice” for succinic gelatin electrolyte sodium acetate injection approved and issued by the State Drug Administration. The succinyl gelatin electrolyte sodium acetate injection declared by Baiyi Pharmaceutical, a wholly-owned subsidiary of the company, was developed using Succinylated Electrolytes Injection certified by B.Braun Melsungen AG as a reference preparation. This product is used as a colloidal plasma volume substitute dissolved in an isotonic electrolyte balanced solution, and is used for the treatment of: 1. Relative or absolute hypovolemia and shock. 2. Combined medication with crystal solution as a component of the infusion solution participates in the process of extracorporeal circulation.

Weixinkang announced on April 16 that Inner Mongolia Baiyi Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Drug Clinical Trial Approval Notice” for succinic gelatin electrolyte sodium acetate injection approved and issued by the State Drug Administration. The succinyl gelatin electrolyte sodium acetate injection declared by Baiyi Pharmaceutical, a wholly-owned subsidiary of the company, was developed using Succinylated Electrolytes Injection certified by B.Braun Melsungen AG as a reference preparation. This product is used as a colloidal plasma volume substitute dissolved in an isotonic electrolyte balanced solution, and is used for the treatment of: 1. Relative or absolute hypovolemia and shock. 2. Combined medication with crystal solution as a component of the infusion solution participates in the process of extracorporeal circulation.